Most importantly, inhibition of hPGDS-catalyzed PGD2 production upon LPS activation in human precision-cut lung slices restricted pro-inflammatory cytokine secretion and, thus, revealed a novel therapeutic target for uncontrolled acute lung inflammation. Here, HPGDS is linked to inflammatory response.